![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Fundamental insights into the pathogenesis of inflammatory bowel diseases (IBD) have led to the development of new therapies and lots of experimental compounds in the pipeline. Our treatment of IBD is therefore constantly evolving. In this editorial, we postulate that bi- or even polyspecific therapy will be an important mainstay of future IBD treatment. Moreover, we highlight some promising new therapeutic concepts currently under investigation and point at the outstanding and growing importance of personalized medicine to assign drugs from the increasing pool of options to the individual patient.
Financial & competing interests disclosure
S Zundler is supported by the Interdisciplinary Center for Clinical Research (IZKF) programme of the University Erlangen-Nuremberg, Germany. The research of MF Neurath is supported by the Clinical Research Group (CEDER) of the German Research Council (DGF), the DFG Collaborative Research Centers 643, 796 and 1181, the German Cancer Aid Organization, the United European Gastroenterology Research Prize, the DFG Graduate School of Excellence in Advanced Optical Technologies, the Excellence Programme (Ludwig Demling Center) and the IZKF and ELAN programmes of the University Erlangen-Nuremberg. He has served as an advisor for MSD, AbbVie, Janssen, Boehringer Ingelheim, Pentax and Giuliani. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Additional information
Notes on contributors
Sebastian Zundler
